Challenges and Benefits of Patient-Based Phase I Trials
Contributor:
Pharma IQ
Posted: 05/05/2011 12:00:00 AM EDT | 0
Posted: 05/05/2011 12:00:00 AM EDT | 0
|
Pharma IQ held a Q&A session with Dr. James Dow, Director of Clinical Pharmacology & DMPK, (OSI) Prosidion to gain a few insights into phase I clinical development and patient-based phase I trials.
How do you feel the clinical trial landscape changed in the past 5 years?
Clearly the trend to include patients in early
-
Interoperability a Concern in 82.4% of Laboratories Progressing Toward the 'Paperless' Ideal -
Pharma IQ Top Blogger Awards 2011 - Legal & Regulatory -
Realising the Demand for Affordable Healthcare: Opportunities and Challenges -
Strategies to Improve Global Patient Adherence -
The Role of Cessation Services in Quitting Smoking and Future Directions -
What Drives a Best Practice Sourcing Strategy? -
Constructing an Integrated Chemical and Test Data Management System to Industrial Standards -
Top Tips for CDISC Implementation -
Creating a Blueprint for Healthcare Facility Planning, Construction, Commissioning and Management -
Balancing Ethics with Economy in Outsourced Clinical Trials
* = required.
Not a member yet? Sign up
Events of Interest
-
Taking EDC to the next level: Moving from point solutions to an eClinical ecosystem
April 4, 2013
Register Now -
Use of Cardiac Safety Data in Early Phase Trials to Supplement or Replace a Thorough QT Trial
June 11, 2012
Register Now -
Site Quality Management and Risk-Based Monitoring: A New Approach
December 4, 2012
Register Now -
Outlicensing – and Beyond
November 8, 2012
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!